HE4、Sp1在上皮性卵巢癌中的表达及其临床意义

Expression of HE4 and Sp1 and their clinical significance in ovarian carcinomas

目的探讨人附睾蛋白4(HE4)和转录因子Sp1在卵巢癌中的表达及其临床价值。方法应用免疫组化法检测40例卵巢癌和20例卵巢上皮性良性卵巢肿瘤组织中HE4、Sp1的表达。结果 HE4在卵巢癌中的阳性表达率(80.00%)明显高于良性上皮性肿瘤(20.00%),差异有统计学意义(P<0.01);HE4在各种病理类型卵巢癌中均表达,在浆液性卵巢癌中表达率最高(92.59%),其次为子宫内膜样癌(71.43%);HE4在中低分化卵巢癌阳性表达率(85.71%)高于高分化者(40.00%),差异有统计学意义(P<0.05),而与卵巢癌FIGO分级及是否伴有淋巴结转移无明显相关性。Sp1在卵巢癌中的阳性表达率(42.50%)高于良性上皮性肿瘤组(15.00%),差异有统计学意义(P<0.05);Sp1在浆液性癌、黏液性癌、内膜样癌中均有表达,表达率差异无统计学意义(P>0.0 5);Sp1在晚期卵巢癌中表达阳性率(57.14%)高于早期卵巢癌(26.32%),中低分化组中阳性率(48.57%)高于高分化组(0.00%),差异均有统计学意义(P<0.05),但与淋巴转移情况无关。HE4及Sp1在上皮性卵巢癌组织中的表达呈正相关(r=0.496,P<0.05)。结论 HE4、Sp1与卵巢癌的发生、发展关系密切,HE4及Sp1有望成为卵巢癌诊断、治疗的新靶点。

Objective To investigate the expression of humanepididymis protein 4（ HE4） and transcription factor Sp1 in epithelial ovarian carcinomas（EOC） and their clinical significance. Methods Immunohistochemical staining was used to detect the expression of HE4 and Sp1 proteins in 40 cases of EOC and 20 cases of benign epithelial ovarian tumors. Results There was statistical difference of positive HE4 expression rate between the EOC（80.00%） and the benign ovarian tumors（20.00%）. Its expression in tumors was restricted to certain histologic subtype.92.59% of serous and 71.43% of endometrioid EOC expressed HE4. The HE4 protein positive expression rate of the moderately and poorly differentiated groups（85.71%） was higher than well differentiation group（ 40.00%）（P〈0.05）. There was no relationship of HE4 expression rate with FIGO stages or lymph node metastasis. There was statistical difference of positive Sp1 expression rate between the EOC（42.50%） and the benign ovarian tumors（15.00%）.There was no statistical difference of Sp1 expression rate with different histologic subtypes. The Sp1 positive expression rate was higher in ovarian cancer patients with the advanced stages（57.14%） compared with the early stages（26.32%） and the moderately and poorly differentiated groups（48.57%） with well differentiation group（0.00%）（P〈0.05）. There was no statistical difference of Sp1 expression rate in ovarian cancer patients with lymph node metastasis or not.HE4 expression was positively related to Sp1 expression in ovarian cancer（r=0.496, P〈0.05）. Conclusions HE4 and Sp1 involved in the carcinogenesis and progression of ovarian carcinoma. They may be novel targets of diagnosis and treatment of ovarian carcinoma.